BIVI
Biovie Inc
NASDAQ: BIVI · HEALTHCARE · BIOTECHNOLOGY
$1.26
-5.26% today
Updated 2026-07-29
Market cap
$10.11M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.79
Dividend yield
—
52W range
$1 – $8
Volume
0.2M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-20.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$5.00
+296.83%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -20.00 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.44M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-26.08M | $-50.26M | $-32.12M | $-17.54M | $-5.27M |
| EPS | — | — | — | — | $-3.79 |
| Free cash flow | $-18.99M | $-40.25M | $-27.95M | $-19.03M | $-7.44M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Biovie Inc trades at $1.26. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -20.00, it sits in the distress.
Frequently asked questions
What is Biovie Inc's stock price?
Biovie Inc (BIVI) trades at $1.26.
Is Biovie Inc overvalued?
Biovie Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Biovie Inc (BIVI)?
The 12-month analyst consensus target is $5.00, about 296.8% above the current $1.26. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Biovie Inc's Altman Z-Score is -20.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-127.61%
Beta0.58
50D MA$1.68
200D MA$1.51
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—